Athersys Inc Stock (OTC:ATHX), Trade Ideas

Athersys

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AGBA

AGRI

AMAM

ANEB

ASMB

ATHX

BKYI

BPTH

COCO

CTKB

ERIC

EVLO

GLUE

GPAK

ITOS

LXRX

METC

MLEC

NKTX

NTCT

NVDA

NVNI

NVVE

OPGN

RANI

SFBS

SMMT

SPRC

WISA

XXII

Gainers


	SciSparc Ltd.  (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.


Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Pre-Market Outlook

AVGR

CNET

JAGX

NCNA

PCSA

VTGN

XTLB

YGMZ

Gainers


	SciSparc Ltd.  (NASDAQ: SPRC) shares surged 79.5% to $5.08 in pre-market trading after falling around 7% on Monday. SciSparc recently regained compliance with the Nasdaq Minimum Bid Price Notification.


Why Vistagen Therapeutics Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

ABAT

AGIL

AKRO

ASST

ASTR

BCEL

BTWN

BXRX

CELU

CHPT

CMND

DADA

ELYS

ETWO

EXAI

FBYD

FEAM

GDHG

HOFV

HUBC

HYLN

INSP

INTZ

LXFR

MGRX

NVAX

ORGN

OTRK

PHIO

PRZO

RETO

SHCR

SILK

SPCB

TCBP

TMDX

Tempest Therapeutics, Inc. - Common Stock

TPST

VINO

VJET

VOXX

VSCO

VSME

WHLR

Gainers


	Tempest Therapeutics, Inc. (NASDAQ: TPST) shares jumped 1067% to $2.80 after the company released new data demonstrating superiority of TPST-1120 arm across multiple study endpoints in first-line hepatocellular carcinoma study.


Why Astra Space Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Athersys Inc

Earnings

Athersys Q3 EPS $(0.15)

<h3>Gainers</h3>
<ul>
<li>Biocept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOC#NASDAQ">BIOC</a>) shares moved upwards by 109.4% to $1.07 during Tuesday's after-market session. Trading volume for this security closed at 4.8 million, accounting for 264.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.8 million. </li>
<li>Intelligent Bio Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) shares moved upwards by 31.44% to $0.4. At the close, Intelligent Bio Solutions's trading volume reached 2.0 million shares. This is 1402.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $1.8 million. </li>
<li>RVL Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVLP#NASDAQ">RVLP</a>) stock rose 17.45% to $0.06. RVL Pharmaceuticals's trading volume hit 18.7 million shares by close, accounting for 104.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $6.6 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares rose 14.94% to $0.89. The market value of their outstanding shares is at $10.4 million. </li>
<li>Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) shares moved upwards by 8.92% to $1.83. The company's market cap stands at $30.8 million. </li>
<li>PaxMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXMD#NASDAQ">PXMD</a>) stock rose 7.61% to $0.26. The market value of their outstanding shares is at $4.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Athersys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHX#NASDAQ">ATHX</a>) shares fell 43.9% to $0.06 during Tuesday's after-market session. Athersys's trading volume hit 45.3 million shares by close, accounting for 2010.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $1.5 million. </li>
<li>Eiger BioPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EIGR#NASDAQ">EIGR</a>) stock fell 9.67% to $0.27. The company's market cap stands at $12.0 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares declined by 7.53% to $2.95. The market value of their outstanding shares is at $1.6 million. </li>
<li>Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) shares decreased by 6.6% to $34.4. The market value of their outstanding shares is at $2.4 billion. </li>
<li>Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) stock fell 5.59% to $322.0. The market value of their outstanding shares is at $9.3 billion. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock fell 5.49% to $0.86. The company's market cap stands at $10.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIOC

EIGR

Intelligent Bio Solutions Inc. - Common Stock

INBS

PXMD

RARE

RVLP

SXTC

VRPX

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>SciSparc Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprc#NASDAQ">SPRC</a>) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.</li>
<li>Assembly Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asmb#NASDAQ">ASMB</a>) gained 120% to $1.5982 after the company and Gilead announced they entered into a 12-year partnership to advance the research and development of novel antiviral therapies.</li>
<li>Olink Holding AB (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/olk#NASDAQ">OLK</a>) shares climbed 65.8% to $24.84 after Thermo Fisher Scientific announced it will acquire the company.</li>
<li>MoneyHero Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mny#NASDAQ">MNY</a>) surged 33.7% to $3.40.</li>
<li>OpGen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opgn#NASDAQ">OPGN</a>) gained 32.7% to $1.20.</li>
<li>FLJ Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flj#NASDAQ">FLJ</a>) jumped 29.3% to $0.2689.</li>
<li>Anebulo Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aneb#NASDAQ">ANEB</a>) gained 22.5% to $2.0950.</li>
<li>Ramaco Resources, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/metc#NASDAQ">METC</a>) rose 20.2% to $11.73.</li>
<li>Aurora Mobile Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jg#NASDAQ">JG</a>) shares climbed 19.8% to $0.1593 after gaining 8% on Monday.</li>
<li>Nkarta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nktx#NASDAQ">NKTX</a>) rose 18.5% to $1.75 as the company received FDA clearance of IND application for NKX019 in lupus nephritis.</li>
<li>AgriFORCE Growing Systems Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agri#NASDAQ">AGRI</a>) gained 18% to $3.0905.</li>
<li>Gamer Pakistan Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gpak#NASDAQ">GPAK</a>) gained 16.8% to $1.46.</li>
<li>Summit Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smmt#NASDAQ">SMMT</a>) rose 16% to $2.03.</li>
<li>Meiwu Technology Company Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wnw#NASDAQ">WNW</a>) shares rose 15.4% to $0.1062 after falling 4% on Monday.</li>
<li>WiSA Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wisa#NASDAQ">WISA</a>) shares gained 12.8% to $0.28 after falling 40% on Monday. WiSA Technologies announced pricing of $4.8 million public offering of Series B convertible redeemable preferred stock and warrants.</li>
<li>iTeos Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/itos#NASDAQ">ITOS</a>) jumped 12.8% to $9.77.</li>
<li>Athersys, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/athx#NASDAQ">ATHX</a>) shares gained 12.3% to $0.1102. Athersys extended near term liquidity with proceeds from warrant inducement and global ARDS license with Healios to explore strategic alternatives.</li>
<li>Moolec Science SA (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mlec#NASDAQ">MLEC</a>) climbed 12% to $2.80. Moolec Science secured $21 million investment from Grupo Insud, bolstering its food ingredient innovations.</li>
<li>V.F. Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vfc#NYSE">VFC</a>) gained 10.1% to $17.82. Engaged Capital has built a big stake in VF Corp, according to the Wall Street Journal.</li>
<li>AGBA Group Holding Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agba#NASDAQ">AGBA</a>) rose 8.9% to $0.5336.</li>
<li>Cytek Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctkb#NASDAQ">CTKB</a>) gained 8.6% to $5.24.</li>
<li>Under Armour, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uaa#NYSE">UAA</a>) rose 7.3% to $7.51.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Evelo Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evlo#NASDAQ">EVLO</a>) shares fell 50.2% to $1.4501. Evelo Biosciences released top-line results from its Phase 2 clinical study with EDP2939 in moderate psoriasis.</li>
<li>Monte Rosa Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glue#NASDAQ">GLUE</a>) fell 19.9% to $4.0050 as the company announced interim data from the Phase 1 dose escalation part of its ongoing phase 1/2 study of MRT-2359 in patients with MYC-driven solid tumors.</li>
<li>Nuvve Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvve#NASDAQ">NVVE</a>) fell 19.1% to $0.3161 after gaining over 9% on Monday.</li>
<li>NetScout Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntct#NASDAQ">NTCT</a>) fell 18.2% to $22.58 after the company reported weak preliminary results for the second quarter and lowered its FY24 guidance.</li>
<li>BIO-key International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bkyi#NASDAQ">BKYI</a>) fell 17.4% to $0.4299 after the company filed for offering of units of up to $10 million.</li>
<li>Bio-Path Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpth#NASDAQ">BPTH</a>) declined 16.5% to $0.5678.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxrx#NASDAQ">LXRX</a>) fell 10.4% to $1.2187.</li>
<li>DXC Technology Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dxc#NYSE">DXC</a>) fell 9.9% to $20.05 after Wolfe Research downgraded the stock from Peer Perform to Underperform.</li>
<li>The Vita Coco Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coco#NASDAQ">COCO</a>) fell 9.7% to $24.29.</li>
<li>Ambrx Biopharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amam#NASDAQ">AMAM</a>) fell 8.7% to $10.44 after declining 19% on Monday. Ambrx Biopharma announced that two abstracts detailing updated safety and efficacy data from the ongoing Phase 1/2 trial, APEX-01, evaluating ARX517 for metastatic castration-resistant prostate cancer (mCRPC) were made available as part of the 2023 European Society of Medical Oncology Congress 2023 meeting.</li>
<li>Rani Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rani#NASDAQ">RANI</a>) fell 8.5% to $2.01 after gaining 11% on Monday.</li>
<li>Nvni Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvni#NASDAQ">NVNI</a>) fell 8.4% to $3.18.</li>
<li>VMware, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vmw#NYSE">VMW</a>) fell 7% to $166.33.</li>
<li>ServisFirst Bancshares, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sfbs#NASDAQ">SFBS</a>) declined 6.1% to $49.65 after the company reported third-quarter earnings.</li>
<li>22nd Century Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xxii#NASDAQ">XXII</a>) shares fell 5.4% to $0.5201 after the company reported pricing of $5.25 million public offering.</li>
<li>NVIDIA Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) declined 4.6% to $439.95. The U.S. government divulged plans to halt shipments to China of more advanced AI chips designed by Nvidia and others, citing military threats.</li>
<li>The Bank of New York Mellon Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bk#NYSE">BK</a>) fell 4.5% to $39.99 following third-quarter results.</li>
<li>Telefonaktiebolaget LM Ericsson (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eric#NASDAQ">ERIC</a>) shares fell 3.6% to $4.5899 after the company reported downbeat third-quarter sales. Ericsson expects lower than-normal seasonality in sales between Q3 and Q4 for Networks and Cloud Software and Services.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/10/35280330/how-to-earn-500-a-month-from-charles-schwab-stock-following-q3-earnings"> How To Earn $500 A Month From Charles Schwab Stock Following Q3 Earnings</a>

Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) shares increased by 108.0% to $1.51 during Tuesday's pre-market session. The company's market cap stands at $79.4 million. </li>
<li>Olink Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLK#NASDAQ">OLK</a>) stock moved upwards by 67.22% to $25.05. The market value of their outstanding shares is at $3.1 billion. </li>
<li>Athersys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHX#NASDAQ">ATHX</a>) shares moved upwards by 33.84% to $0.13. The market value of their outstanding shares is at $3.5 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) stock rose 16.58% to $5.83. The company's market cap stands at $289.4 million. </li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) shares rose 16.21% to $2.15. The company's market cap stands at $49.1 million. </li>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) shares moved upwards by 13.38% to $7.0. The market value of their outstanding shares is at $250.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Evelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLO#NASDAQ">EVLO</a>) shares decreased by 55.3% to $1.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $24.4 million. </li>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) shares declined by 13.8% to $1.25. The company's market cap stands at $26.7 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares fell 13.36% to $0.37. The market value of their outstanding shares is at $2.1 million. </li>
<li>Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) shares decreased by 12.47% to $1.51. The company's market cap stands at $79.2 million. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares fell 12.27% to $0.49. The market value of their outstanding shares is at $12.0 million. </li>
<li>XTL Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) shares decreased by 11.75% to $0.75. The market value of their outstanding shares is at $4.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PPBT

RDHL

VIGL

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>SciSparc Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprc#NASDAQ">SPRC</a>) shares surged 79.5% to $5.08 in pre-market trading after falling around 7% on Monday. SciSparc recently regained compliance with the Nasdaq Minimum Bid Price Notification.</li>
<li>WiSA Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wisa#NASDAQ">WISA</a>) shares rose 76.4% to $0.4380 in pre-market trading after falling 40% on Monday. WiSA Technologies announced the pricing of a $4.8 million public offering of Series B convertible redeemable preferred stock and warrants.</li>
<li>Athersys, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/athx#NASDAQ">ATHX</a>) shares gained 51.5% to $0.1487 in pre-market trading. Athersys extended near-term liquidity with proceeds from warrant inducement and a global ARDS license with Healios to explore strategic alternatives.</li>
<li>Aurora Mobile Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jg#NASDAQ">JG</a>) shares climbed 50.8% to $0.2005 in pre-market trading after gaining 8% on Monday.</li>
<li>ZW Data Action Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cnet#NASDAQ">CNET</a>) rose 30.8% to $1.23 in pre-market trading after declining 13% on Monday.</li>
<li>Meiwu Technology Company Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wnw#NASDAQ">WNW</a>) shares rose 30.4% to $0.12 in pre-market trading after falling 4% on Monday.</li>
<li>Jaguar Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jagx#NASDAQ">JAGX</a>) gained 13.5% to $0.4085 in pre-market trading after gaining more than 12% on Monday.</li>
<li>Vistagen Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtgn#NASDAQ">VTGN</a>) shares rose 12.6% to $3.57 in pre-market trading after a 13G filing showed Citadel Advisors LLC reported a 5.6% stake in the company.</li>
<li>AGBA Group Holding Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agba#NASDAQ">AGBA</a>) rose 12.2% to $0.55 in pre-market trading.</li>
<li>Akso Health Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ahg#NASDAQ">AHG</a>) shares jumped 8.6% to $2.01 in pre-market trading. Akso Health Group recently regained compliance with Nasdaq&#39;s Minimum Bid Price Requirement.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nuvve Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvve#NASDAQ">NVVE</a>) dipped 33.5% to $0.2599 in pre-market trading after gaining over 9% on Monday.</li>
<li>NetScout Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntct#NASDAQ">NTCT</a>) shares fell 23% to $21.24 in pre-market trading after the company reported weak preliminary results for the second quarter and lowered its FY24 guidance.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pcsa#NASDAQ">PCSA</a>) shares fell 18.6% to $0.4547 in pre-market trading, after jumping 16% on Monday.</li>
<li>MingZhu Logistics Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ygmz#NASDAQ">YGMZ</a>) shares fell 14.5% to $0.5731 in pre-market trading after jumping around 38% on Monday.</li>
<li>Rani Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rani#NASDAQ">RANI</a>) fell 13.5% to $1.90 in pre-market trading after gaining 11% on Monday.</li>
<li>Ambrx Biopharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amam#NASDAQ">AMAM</a>) fell 13.4% to $9.90 in pre-market trading after declining 19% on Monday. Ambrx Biopharma announced that two abstracts detailing updated safety and efficacy data from the ongoing Phase 1/2 trial, APEX-01, evaluating ARX517 for metastatic castration-resistant prostate cancer (mCRPC) were made available as part of the 2023 European Society of Medical Oncology Congress 2023 meeting.</li>
<li>22nd Century Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xxii#NASDAQ">XXII</a>) shares fell 11.9% to $0.4840 in pre-market trading after reporting a proposed public offering.</li>
<li>XTL Biopharmaceuticals Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xtlb#NASDAQ">XTLB</a>) fell 11.8% to $0.7528 in pre-market after dipping around 15% on Monday.</li>
<li>NuCana plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncna#NASDAQ">NCNA</a>) shares fell 11.7% to $0.50 in pre-market trading after declining around 12% on Monday. NuCana presented data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023.</li>
<li>Avinger, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avgr#NASDAQ">AVGR</a>) shares fell 11.2% to $5.71 in pre-market trading, after gaining over 21% on Monday.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/10/35280296/investor-fear-eases-ahead-of-big-earnings"> Investor Fear Eases Ahead Of Big Earnings</a>

Offerings

Athersys Warrant Exercise Inducement Offer Letter To Raise Gross Proceeds Of Up To ~$3.9M From The Exercise Of 28,124,590 Warrants And Received The First Tranche Payment Of $1.5M From Healios K.K. Under The ARDS Global License

Athersys, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ATHX#NASDAQ">ATHX</a>), ("Athersys" or the "Company") a cell therapy and regenerative medicine company developing MultiStem&#xAE; (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K. ("Healios") under the acute respiratory distress syndrome ("ARDS") global license.
On October 11, 2023, Athersys entered into a warrant exercise inducement offer letter (the "Inducement Letter") with a holder of certain existing warrants ("Holder") to receive new warrants to purchase up to a number of shares of common stock equal to 200% (the "Inducement Warrants") of the number of warrant shares issued pursuant to the exercise of such certain existing warrants to purchase shares of common stock (the "Existing Warrants") pursuant to which the Holder agreed to exercise for cash their Existing Warrants to purchase up to 28,124,590 shares of the Company's common stock, at a reduced exercise price of $0.1395 per share (the "Reduced Exercise Price"). The closing of this transaction occurred on October 16, 2023. The Company engaged A.G.P./Alliance Global Partners ("AGP") to act as its financial advisor in connection with the transactions summarized above and will pay AGP a fee of $275,000.
On October 12, 2023, the Company received a payment of $1.5 million per the recently executed Memorandum of Understanding ("MOU") with Healios for global rights to develop and commercialize MultiStem for the treatment of ARDS. Under the terms of the MOU, Athersys expects to receive additional near-term payments totaling between $1.5 million and $3 million and may receive up to $150 million in potential development and sales milestones and additional royalties.
Net proceeds from the exercise of the Existing Warrants and the ARDS license with Healios will extend the Company's liquidity to continue to explore strategic alternatives.
Athersys has engaged Outcome Capital ("Outcome"), a life sciences and healthcare advisory and strategic investment banking firm, to assist the Company with evaluating strategic alternatives, which could include, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license, or other acquisition of assets with the goal of maximizing shareholder value. This process may not result in any transaction and the Company does not intend to disclose additional details unless and until it has entered into a specific transaction. However, in the event Athersys is unable to enter into a strategic transaction or obtain adequate financing, it expects to have to file for protection under the bankruptcy laws to allow the Company to conduct an orderly wind down of operations.
About MultiStem&#xAE;
MultiStem&#xAE; (invimestrocel) cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. MultiStem&#xAE; therapy's potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The therapy represents a unique "off-the-shelf" stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form and is administered without tissue matching or the need for immune suppression. Based upon its efficacy profile, its novel mechanisms of action and a favorable and consistent tolerability demonstrated in clinical studies, we believe that MultiStem&#xAE; therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need.

Athersys Extends Near Term Liquidity with Proceeds From Warrant Inducement And Global ARDS License With Healios To Explore Strategic Alternatives

<h3>Gainers</h3>
<ul>
<li>Tempest Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tpst#NASDAQ">TPST</a>) shares jumped 1067% to $2.80 after the company released new data demonstrating superiority of TPST-1120 arm across multiple study endpoints in first-line hepatocellular carcinoma study.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/phio#NASDAQ">PHIO</a>) jumped 59.5% to $2.17. Phio Pharmaceuticals presented new data for targeting of BRD4 with its INTASYL&trade; compound PH-894.</li>
<li>Tupperware Brands Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tup#NYSE">TUP</a>) surged 42.5% to $2.14.</li>
<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/whlr#NASDAQ">WHLR</a>) gained 41.4% to $1.2586 after falling 7% on Tuesday.</li>
<li>ReTo Eco-Solutions, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/reto#NASDAQ">RETO</a>) jumped 37.3% to $0.7461.</li>
<li>Gaucho Group Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vino#NASDAQ">VINO</a>) shares climbed 32.6% to $1.18 after falling over 12% on Tuesday. Gaucho Group announced its journey towards organic cultivation for select sections of its renowned Pinot Noir and Cabernet Sauvignon vineyards.</li>
<li>Clearmind Medicine Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmnd#NASDAQ">CMND</a>) gained 28.5% to $0.1934.</li>
<li>Celularity Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/celu#NASDAQ">CELU</a>) rose 26.2% to $0.25.</li>
<li>Asset Entities Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asst#NASDAQ">ASST</a>) gained 26% to $0.3870. Asset Entities recently announced it received a notice from the Nasdaq saying that it is not in compliance with the minimum bid price requirement.</li>
<li>Mangoceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgrx#NASDAQ">MGRX</a>) shares climbed 25.3% to $0.7440 after gaining 9% on Tuesday.</li>
<li>Sharecare, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shcr#NASDAQ">SHCR</a>) shares surged 22.8% to $1.1494. On Oct. 3, 2023, John Chadwick submitted a preliminary non-binding proposal to the board on behalf of Claritas Capital, related to the proposed acquisition of all of the Sharecare shares not owned by reporting persons for $1.35 to $1.80 per share in cash.</li>
<li>TC Biopharm (Holdings) Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcbp#NASDAQ">TCBP</a>) rose 22.6% to $0.4298.</li>
<li>voxeljet AG (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vjet#NASDAQ">VJET</a>) gained 22.3% to $1.26 after the company announced it was selected for a $14.9 million contract alongside GE Research to develop advanced manufacturing technologies to enable the U.S. energy transition.</li>
<li>VOXX International Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/voxx#NASDAQ">VOXX</a>) shares jumped 22% to $9.51 as the company reported stronger-than-expected sales for its second quarter.</li>
<li>Baudax Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bxrx#NASDAQ">BXRX</a>) gained 21.7% to $0.3188.</li>
<li>Origin Materials, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/orgn#NASDAQ">ORGN</a>) jumped 20.3% to $1.1650. Origin Materials announced commencement of commercial-scale production at Origin 1.</li>
<li>AgileThought, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agil#NASDAQ">AGIL</a>) rose 20% to $0.1775. On Oct. 10, 2023, The Bankruptcy Court entered an order approving AgileThought Parties&#39; and stalking horse buyer&#39;s entry into agreement.</li>
<li>Ontrak, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otrk#NASDAQ">OTRK</a>) gained 18.1% to $0.8380.</li>
<li>Golden Heaven Group Holdings Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gdhg#NASDAQ">GDHG</a>) gained 16% to $9.25.</li>
<li>Atreca, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcel#NASDAQ">BCEL</a>) shares surged 14.3% to $0.24 after falling around 9% on Tuesday.</li>
<li>5E Advanced Materials, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/feam#NASDAQ">FEAM</a>) rose 13.7% to $3.16.</li>
<li>TD Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glg#NASDAQ">GLG</a>) climbed 13.3% to $0.1307.</li>
<li>Coffee Holding Co., Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jva#NASDAQ">JVA</a>) gained 12.8% to $0.7501.</li>
<li>Athersys, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/athx#NASDAQ">ATHX</a>) shares gained 11.7% to $0.1340, after falling 60% on Tuesday. Athersys said it intends to conduct additional data analysis with independent statisticians because the sample size in the Phase 3 MASTERS-2 is insufficiently powered to achieve the primary endpoint.</li>
<li>Elys Game Technology, Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elys#NASDAQ">ELYS</a>) climbed 10% to $0.5501. Elys Game Technology disclosed the expansion of its footprint in Washington, D.C. with the addition of a third sportsbook location, Grand Central Sportsbook on H Street.</li>
<li>Novavax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvax#NASDAQ">NVAX</a>) rose 9.2% to $8.06. Novavax will present study findings during two posters sessions at IDWeek 2023, October 11-15, and three oral presentations at World Vaccine Congress Europe 2023, October 16-19.</li>
<li>AZZ Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/azz#NYSE">AZZ</a>) surged 8.9% to $50.00 as the company posted better-than-expected results for its second quarter and reaffirmed FY24 guidance.</li>
<li>Dada Nexus Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dada#NASDAQ">DADA</a>) climbed 7.7% to $4.8150.</li>
<li>American Battery Technology Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abat#NASDAQ">ABAT</a>) gained 7.6% to $7.41.</li>
<li>Exscientia plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exai#NASDAQ">EXAI</a>) rose 7.5% to $5.01.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Silk Road Medical, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/silk#NASDAQ">SILK</a>) shares fell 52.7% to $6.62 after the company announced preliminary third-quarter revenue results below estimates and issued FY23 revenue guidance below estimates.</li>
<li>Hyliion Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hyln#NYSE">HYLN</a>) shares fell 49.6% to $0.6001. The company late Tuesday said it is exploring strategic <a href="https://www.benzinga.com/money/best-options-to-buy-this-week/">options</a> for its powertrain business due to the evolving commercial vehicle electrification industry, slow market adoption and the need for continued investment and regulatory compliance.</li>
<li>E2open Parent Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/etwo#NYSE">ETWO</a>) fell 46.4% to $2.3550 as the company posted downbeat results for its second quarter and named Andrew Appel as interim CEO, effective immediately.</li>
<li>SuperCom Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spcb#NASDAQ">SPCB</a>) declined 42.7% to $0.5047 after surging 144% on Tuesday. SuperCom Ltd. is an Israel-based provider of digital identity and cybersecurity products and solutions to governments and private and public organizations throughout the world.</li>
<li>ParaZero Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/przo#NASDAQ">PRZO</a>) shares fell 31.2% to $1.67 after declining 10% on Tuesday. ParaZero Technologies recently announced an Australian regulator approved first commercial drone flights in populated areas and near people using ParaZero safety systems.</li>
<li>HUB Cyber Security Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hubc#NASDAQ">HUBC</a>) dipped 28.8% to $0.3720.</li>
<li>Hall of Fame Resort &amp; Entertainment Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hofv#NASDAQ">HOFV</a>) fell 27.8% to $3.25 as the company announced pricing of $2.8 million public offering of 750,000 shares of common stock and accompanying warrant at $3.75 per unit.</li>
<li>The Real Good Food Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rgf#NASDAQ">RGF</a>) fell 27% to $2.24 after the company reported preliminary third quarter financial results and issued FY23 revenue guidance below estimates. Additionally, the company announced the commencement of a public offering.</li>
<li>Bridgetown Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btwn#NASDAQ">BTWN</a>) declined 27% to $5.76.</li>
<li>Falcon&#39;s Beyond Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fbyd#NASDAQ">FBYD</a>) fell 25.6% to $12.20.</li>
<li>AgriFORCE Growing Systems Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agri#NASDAQ">AGRI</a>) declined 25% to $2.91.</li>
<li>Astra Space, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/astr#NASDAQ">ASTR</a>) fell 22% to $1.02. The company is contemplating divesting a majority share of 51% in its in-space propulsion arm, among other potential sales strategies, according to a report from Bloomberg.</li>
<li>Intrusion Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intz#NASDAQ">INTZ</a>) fell 21.3% to $0.34. The stock traded lower, likely on profit-taking following Tuesday&#39;s surge, after the company was awarded a $5 million multi-year shield agreement with a telecommunications provider.</li>
<li>Outset Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/om#NASDAQ">OM</a>) declined 20.7% to $7.68.</li>
<li>Akero Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akro#NASDAQ">AKRO</a>) fell 19.8% to $14.55. Morgan Stanley maintained Akero Therapeutics with an Overweight and lowered the price target from $70 to $33.</li>
<li>DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>) fell 19.5% to $73.28 in reaction to Novo Nordisk&rsquo;s stopping semaglutide kidney outcomes trial FLOW based on early signs of efficacy.</li>
<li>VS MEDIA Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vsme#NASDAQ">VSME</a>) fell 19.3% to $1.13.</li>
<li>Fresenius Medical Care AG &amp; Co. KGaA (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fms#NYSE">FMS</a>) shares fell 18.5% to $17.08. Shares of dialysis providers and kidney care stocks traded lower after Novo Nordisk stopped its semaglutide kidney outcomes trial early based on early signs of efficacy.</li>
<li>Luxfer Holdings PLC (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lxfr#NYSE">LXFR</a>) fell 14.8% to $11.45 after it reported third-quarter preliminary results.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smx#NASDAQ">SMX</a>) fell 13.7% to $2.47. SMX shares jumped 69% on Tuesday after the company announced it secured a majority stake in True Gold Consortium.</li>
<li>Perimeter Solutions, SA (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/prm#NYSE">PRM</a>) declined 13.3% to $3.3550. UBS downgraded Perimeter Solutions from Buy to Neutral and lowered the price target from $7 to $4.25.</li>
<li>Inspire Medical Systems, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/insp#NYSE">INSP</a>) fell 13% to $161.21.</li>
<li>ChargePoint Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chpt#NYSE">CHPT</a>) declined 13% to $3.9050 after the company announced it raised $232 million to support its path to profitability in 2024.</li>
<li>Mobilicom Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mob#NASDAQ">MOB</a>) shares fell 12.2% to $1.80, after jumping over 44% on Tuesday. The Bank of New York Mellon reported in a filing late Monday that it increased its stake in the company.</li>
<li>TransMedics Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) fell 11.5% to $46.08.</li>
<li>Victoria&#39;s Secret &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vsco#NYSE">VSCO</a>) fell 10.4% to $14.65.</li>
<li>Baxter International Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bax#NYSE">BAX</a>) shares declined 9.1% to $33.92. Baxter International named Joel Grade as executive vice president and chief financial officer.</li>
<li>The Brink&#39;s Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bco#NYSE">BCO</a>) fell 8.6% to $67.11.</li>
<li>Northern Oil and Gas, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nog#NYSE">NOG</a>) fell 4% to $39.22 as the company priced public offering of 6.5 million common shares for gross proceeds of $252.7 million.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/23/10/35190839/top-5-consumer-stocks-that-may-implode-this-quarter"> Top 5 Consumer Stocks That May Implode This Quarter </a>

Why Astra Space Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) shares increased by 692.0% to $1.9 during Wednesday's pre-market session. The company's market cap stands at $25.3 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares increased by 23.63% to $1.01. The company's market cap stands at $4.2 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares rose 21.21% to $0.24. The company's market cap stands at $45.8 million. </li>
<li>Athersys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHX#NASDAQ">ATHX</a>) shares rose 15.5% to $0.14. The company's market cap stands at $3.7 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) stock increased by 15.17% to $1.6. The company's market cap stands at $3.5 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock rose 14.51% to $0.65. The market value of their outstanding shares is at $25.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Silk Road Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILK#NASDAQ">SILK</a>) shares decreased by 50.3% to $6.95 during Wednesday's pre-market session. The company's market cap stands at $269.8 million. </li>
<li>DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) stock decreased by 17.29% to $75.5. The company's market cap stands at $6.8 billion. </li>
<li>Fresenius Medical Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) shares decreased by 15.57% to $17.69. The market value of their outstanding shares is at $10.3 billion. </li>
<li>Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) stock decreased by 15.38% to $8.2. The market value of their outstanding shares is at $408.2 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) stock decreased by 13.69% to $0.82. The company's market cap stands at $19.3 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock fell 12.97% to $0.3. The company's market cap stands at $7.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KZIA

SBFM

SINT

TRIB

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers
Tempest Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tpst#NASDAQ">TPST</a>) shares rose 279.8% to $0.9115 in pre-market trading, after the company announced it plans to report new and updated data from the global randomized combination study of TPST-1120 in first-line hepatocellular carcinoma in a premarket press release on Oct. 11.
Wheeler Real Estate Investment Trust, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/whlr#NASDAQ">WHLR</a>) shares gained 211% to $2.77 in pre-market trading after falling 7% on Tuesday.
Athersys, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/athx#NASDAQ">ATHX</a>) shares rose 20.7% to $0.14 in pre-market trading, after falling 60% on Tuesday. Athersys said it intends to conduct additional data analysis with independent statisticians because the sample size in the Phase 3 MASTERS-2 is insufficiently powered to achieve the primary endpoint.
Gaucho Group Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vino#NASDAQ">VINO</a>) shares climbed 42.7% to $1.27 in pre-market trading, after falling over 12% on Tuesday. Gaucho Group announced its journey towards organic cultivation for select sections of its renowned Pinot Noir and Cabernet Sauvignon vineyards.
Connexa Sports Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cnxa#NASDAQ">CNXA</a>) rose 34.7% to $2.56 in pre-market trading.
AgileThought, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agil#NASDAQ">AGIL</a>) rose 27.7% to $0.1890 in pre-market trading. On Oct. 10, 2023, the Bankruptcy Court entered an order approving AgileThought Parties&#39; and stalking horse buyer&#39;s entry into agreement.
Mangoceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgrx#NASDAQ">MGRX</a>) shares jumped 24.3% to $0.7360 in pre-market trading after gaining 9% on Tuesday.
Elys Game Technology, Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elys#NASDAQ">ELYS</a>) gained 19.6% to $0.5982 in pre-market trading. Elys Game Technology disclosed the expansion of its footprint in Washington, D.C. with the addition of a third sportsbook location, Grand Central Sportsbook on H Street.
Atreca, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcel#NASDAQ">BCEL</a>) shares surged 15.1% to $0.2417 in pre-market trading, after falling around 9% on Tuesday.
VOXX International Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/voxx#NASDAQ">VOXX</a>) shares rose 11.7% to $8.70 in pre-market trading as the company reported stronger-than-expected sales for its second quarter.
Losers
Silk Road Medical, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/silk#NASDAQ">SILK</a>) fell 38.5% to $8.61 in pre-market trading after the company announced preliminary third-quarter revenue results below estimates and issued FY23 revenue guidance below estimates.
SuperCom Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spcb#NASDAQ">SPCB</a>) fell 25.1% to $0.6588 in pre-market trading, after surging 144% on Tuesday. SuperCom Ltd. is an Israel-based provider of digital identity and cybersecurity products and solutions to governments and private and public organizations throughout the world.
Fresenius Medical Care AG &amp; Co. KGaA (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fms#NYSE">FMS</a>) shares fell 18.2% to $17.14 in pre-market trading.
Mobilicom Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mob#NASDAQ">MOB</a>) shares fell 17.1% to $1.70 in pre-market trading, after jumping over 44% on Tuesday. The Bank of New York Mellon reported in a filing late Monday that it increased its stake in the company.
SMX (Security Matters) Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smx#NASDAQ">SMX</a>) fell 16.7% to $2.39 in pre-market trading. SMX shares jumped 69% on Tuesday after the company announced it secured a majority stake in True Gold Consortium.
DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>) fell 16.5% to $76.23 in pre-market. Rockwell Medical said on Sept. 18, that the company and Davita entered into an amended and restated products purchase agreement.
E2open Parent Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/etwo#NYSE">ETWO</a>) fell 15.3% to $3.72 in pre-market trading as the company posted downbeat results for its second quarter and named Andrew Appel as interim CEO, effective immediately.
ParaZero Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/przo#NASDAQ">PRZO</a>) shares fell 7.4% to $2.25&nbsp;in pre-market trading after declining 10% on Tuesday. ParaZero Technologies recently announced an Australian regulator approved the first commercial drone flights in populated areas and near people using ParaZero safety systems.
Hyliion Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hyln#NYSE">HYLN</a>) shares fell 14.2% to $1.02 in pre-market trading after the company announced a strategic review of alternatives for Electric Powertrain Business.
CASI Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/casi#NASDAQ">CASI</a>) shares fell 11.9% to $2.66 in pre-market trading.
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/10/35182960/fastenal-gears-up-for-q3-print-heres-a-look-at-recent-price-target-changes-by-the-most-accurate-ana"> Fastenal Gears Up For Q3 Print; Here&#39;s A Look At Recent Price Target Changes By The Most Accurate Analysts</a>

CASI

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

Why VOXX International Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) shares increased by 325.0% to $1.02 during Tuesday's after-market session. At the close, Tempest Therapeutics's trading volume reached 17.9 million shares. This is 11313.7% of its average volume over the last 100 days. The company's market cap stands at $13.5 million. </li>
<li>Athersys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHX#NASDAQ">ATHX</a>) stock moved upwards by 22.5% to $0.15. Trading volume for this security closed at 2.1 million, accounting for 467.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.9 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock moved upwards by 19.71% to $0.34. At the close, Cardio Diagnostics Hldgs's trading volume reached 308.4K shares. This is 194.7% of its average volume over the last 100 days. The company's market cap stands at $4.0 million. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) stock increased by 18.21% to $0.39. At the close, Yield10 Bioscience's trading volume reached 512.4K shares. This is 156.3% of its average volume over the last 100 days. The market value of their outstanding shares is at $4.6 million. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock increased by 13.62% to $0.23. The company's market cap stands at $5.7 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares increased by 12.94% to $0.48. The market value of their outstanding shares is at $14.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Silk Road Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILK#NASDAQ">SILK</a>) shares fell 33.9% to $9.25 during Tuesday's after-market session. At the close, Silk Road Medical's trading volume reached 183.1K shares. This is 20.6% of its average volume over the last 100 days. The company's market cap stands at $359.2 million. </li>
<li>DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) stock fell 12.8% to $79.6. This security traded at a volume of 61.7K shares come close, making up 8.6% of its average volume over the last 100 days. The market value of their outstanding shares is at $7.2 billion. </li>
<li>Fresenius Medical Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) shares decreased by 9.31% to $19.0. The company's market cap stands at $11.1 billion. </li>
<li>Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) stock fell 7.4% to $34.56. Baxter Intl's trading volume hit 88.0K shares by close, accounting for 2.0% of its average volume over the last 100 days. The company's market cap stands at $17.5 billion. </li>
<li>PaxMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXMD#NASDAQ">PXMD</a>) stock fell 7.33% to $0.2. The market value of their outstanding shares is at $3.4 million. </li>
<li>Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) stock decreased by 7.13% to $9.0. Today's trading volume for this security ended up closing at 268.5K shares, which is 44.9 percent of its average volume over the last 100 days. The company's market cap stands at $448.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

MBRX

YTEN

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 175 points on Tuesday.
The Dow traded up 0.53% to 33,781.59 while the NASDAQ rose 0.72% to 13,581.64. The S&amp;P 500 also rose, gaining, 0.68% to 4,364.93.
Check This Out: <a href="https://www.benzinga.com/news/earnings/23/10/35145201/walgreens-likely-to-report-lower-q4-earnings-heres-a-look-at-recent-price-target-changes-by-the-mos"> Walgreens Likely To Report Lower Q4 Earnings; Here&#39;s A Look At Recent Price Target Changes By The Most Accurate Analysts</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Materials shares surged by 1.5% on Tuesday.
In trading on Tuesday, information technology shares rose by just 0.1%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Neogen Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/neog#NASDAQ">NEOG</a>) reported weaker-than-expected results for its first quarter on Tuesday.
The company posted quarterly sales of $229 million, an increase of 73.0% Y/Y, missing the consensus of $231.1 million. It reported an adjusted EPS of 11 cents, which missed the consensus of 12 cents.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
SMX (Security Matters) Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smx#NASDAQ">SMX</a>) shares shot up 62% to $2.75 after the company announced it secured a majority stake in True Gold Consortium.
Shares of Intrusion Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intz#NASDAQ">INTZ</a>) got a boost, shooting 59% to $0.5568. Intrusion has been awarded a $5 million agreement with a large telecommunications provider to provide Intrusion Shield support for its data centers.
Startek, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/srt#NYSE">SRT</a>) shares were also up, gaining 29% to $4.2199 as the company agreed to be acquired by funds managed by CSP Management Limited for $4.30 per share in cash.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Akero Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akro#NASDAQ">AKRO</a>) shares dropped 62% to $18.21 after the company reported a 36-week analysis of its Phase 2b SYMMETRY study evaluating the efficacy and safety of its lead product candidate efruxifermin.
Shares of Athersys, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/athx#NASDAQ">ATHX</a>) were down 51% to $0.1471 after the company reported interim analysis results of MASTERS-2 clinical study with multistem in ischemic stroke and signed a Memorandum of Understanding for global ARDS license with Healios.
Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) was down, falling 21% to $23.71 after the company announced results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis.
Also Check This Out:<a href="https://www.benzinga.com/news/23/10/35158866/check-out-3-high-yielding-dividend-stocks-in-energy-sector-from-wall-streets-most-accurate-analysts"> Check Out 3 High-Yielding Dividend Stocks In Energy Sector From Wall Street&#39;s Most Accurate Analysts</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 0.6% to $85.89 while gold traded up 0.6% at $1,875.60.
Silver traded up 0.4% to $22.02 on Tuesday while copper fell 0.4% to $3.6325.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares closed higher today. The eurozone&rsquo;s STOXX 600 gained 1.96% London&rsquo;s FTSE 100 gained 1.82% while Spain&rsquo;s IBEX 35 Index rose 2.19% The German DAX rose 1.95% French CAC 40 climbed 2.01%, while Italy&rsquo;s FTSE MIB Index gained 2.3%.
Industrial production in Italy rose 0.2% month-over-month in August following a revised 0.9% fall in July. Retail sales in the UK rose 2.8% from a year ago in September.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly higher on Tuesday, with Japan&rsquo;s Nikkei 225 gaining 2.43%, China&rsquo;s Shanghai Composite Index falling 0.70% and Hong Kong&rsquo;s Hang Seng Index gaining 0.84%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, rose 0.9%.
Japan&#39;s current account surplus narrowed to JPY 2.280 trillion in August from JPY 2.772 trillion in the prior month, compared to market estimates of JPY 3.091 trillion.
&nbsp;
<h3>Economics</h3>
&nbsp;
The NFIB Small Business Optimism Index fell for a second month to a reading of 90.8 in September from 91.3 in the prior month.
U.S. wholesale inventories fell 0.1% month-over-month in August.
Now Read This: <a href="https://www.benzinga.com/news/23/10/35157619/top-3-tech-and-telecom-stocks-you-may-want-to-dump-in-october"> Top 3 Tech And Telecom Stocks You May Want To Dump In October</a>

Eurozone

Commodities

Global

NEOG

VTYX

Crude Oil Moves Lower; Neogen Posts Downbeat Results

<h3>Gainers</h3>
<ul>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares moved upwards by 33.2% to $0.48 during Tuesday's regular session. The current volume of 13.0 million shares is 535.8% of Inovio Pharmaceuticals's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $128.2 million. </li>
<li>NanoString Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSTG#NASDAQ">NSTG</a>) stock moved upwards by 26.74% to $1.52. Trading volume for this security as of 13:30 EST is 3.2 million, which is 213.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $72.3 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares increased by 21.21% to $0.8. The company's market cap stands at $3.7 million. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) shares rose 20.43% to $3.89. The company's market cap stands at $9.3 million. </li>
<li>Carmell Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock rose 17.7% to $3.39. The market value of their outstanding shares is at $78.2 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) stock moved upwards by 17.08% to $0.51. Trading volume for Vicarious Surgical's stock is 303.0K as of 13:30 EST. This is 29.7% of its average full-day volume over the last 100 days. The company's market cap stands at $87.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>) shares decreased by 63.9% to $17.55 during Tuesday's regular session. Akero Therapeutics's stock is trading at a volume of 21.2 million shares as of 13:30 EST. This is 2889.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $975.5 million. </li>
<li>Athersys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHX#NASDAQ">ATHX</a>) shares decreased by 49.77% to $0.15. Trading volume for this security as of 13:30 EST is 13.6 million, which is 3014.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.0 million. </li>
<li>89bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETNB#NASDAQ">ETNB</a>) shares fell 35.65% to $9.99. 89bio's stock is trading at a volume of 8.2 million shares as of 13:30 EST. This is 848.3% of its average full-day volume over the last 100 days. The company's market cap stands at $754.4 million. </li>
<li>Ventyx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) stock declined by 23.44% to $22.97. The current volume of 2.8 million shares is 510.9% of Ventyx Biosciences's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $1.3 billion. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares fell 23.27% to $0.89. As of 13:30 EST, this security is trading at a volume of 74.6K shares, making up 801.5% of its average full-day volume over the last 100 days. The company's market cap stands at $3.8 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares decreased by 18.55% to $1.01. The current volume of 321.4K shares is 303.5% of Nuwellis's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $1.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTCX

CYCN

ETNB

NSTG

NUWE

PTIX

RBOT

SCNI

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers
SuperCom Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spcb#NASDAQ">SPCB</a>) shares jumped 89% to $0.6805, after falling 13% on Monday.
SMX (Security Matters) Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smx#NASDAQ">SMX</a>) shares climbed 87.1% to $3.18 after the company announced it secured a majority stake in True Gold Consortium.
PowerFleet, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pwfl#NASDAQ">PWFL</a>) gained 42% to $2.80. Powerfleet and MiX Telematics entered into a definitive agreement to form one of the largest mobile asset Internet of Things Software-as-a-Service providers in the world.
SaverOne 2014 Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/svre#NASDAQ">SVRE</a>) rose 31.1% to $0.7010.
Intrusion Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intz#NASDAQ">INTZ</a>) gained 30.4% to $0.4565. Intrusion has been awarded a $5 million agreement with a large telecommunications provider to provide Intrusion Shield support for its data centers.
Startek, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/srt#NYSE">SRT</a>) gained 29.1% to $4.21 as the company agreed to be acquired by funds managed by CSP Management Limited for $4.30 per share in cash.
CISO Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciso#NASDAQ">CISO</a>) shares climbed 29.1% to $0.18. CISO Global said its Argo Edge Cloud Security Platform has been independently valued at $49 million.
Mobilicom Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mob#NASDAQ">MOB</a>) climbed 27.1% to $1.8050, after gaining more than 11% on Monday.
PGT Innovations, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pgti#NYSE">PGTI</a>) surged 21.8% to $31.92.
NanoString Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nstg#NASDAQ">NSTG</a>) gained 20.7% to $1.4506 after the company disclosed third-quarter preliminary results and a reorganization designed to accelerate its path to profitability.
Erasca, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eras#NASDAQ">ERAS</a>) rose 20.6% to $2.6550.
Processa Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pcsa#NASDAQ">PCSA</a>) climbed 19% to $0.2209.
MDxHealth SA (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdxh#NASDAQ">MDXH</a>) gained 18.5% to $2.82. MDxHealth reported preliminary revenues of $19.3 million for the third quarter, representing an increase of 73% year over year.
Lexicon Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxrx#NASDAQ">LXRX</a>) shares surged 15.5% to $1.1550. Lexicon Pharmaceuticals said INPEFA received preferred formulary status with Express Scripts for Medicare patients.
ContraFect Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cfrx#NASDAQ">CFRX</a>) rose 13.4% to $0.5108, after surging more than 12% on Monday.
Canopy Growth Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) gained 13% to $0.7733. Canopy Growth received EU GMP certification from RP Tuebingen, Regional Health Inspectorate of Baden-Wuerttemberg for its cannabis cultivation facility in Kincardine, Ontario.
Coherent Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cohr#NYSE">COHR</a>) climbed 12% to $34.73 after the company announced Denso Corporation and Mitsubishi Electric Corporation have agreed to invest an aggregate $1 billion in its silicon carbide business.
Opendoor Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/open#NASDAQ">OPEN</a>) gained 8% to $2.6250.
Rackspace Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rxt#NASDAQ">RXT</a>) gained 8.1% to $1.67.
Hyatt Hotels Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/h#NYSE">H</a>) gained 5.6% to $110.33 after it was announced the company will join the S&amp;P MidCap 400.
Immunic, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imux#NASDAQ">IMUX</a>) shares rose 5.6% to $1.68 after the company announced interim data from its phase 2 CALLIPER trial of nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS).
Unity Software Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/u#NYSE">U</a>) shares surged 4.1% to $30.92 after the company announced a CEO transition. Unity announced that John Riccitiello will retire as chairman, president and CEO, effective immediately.
Losers
Akero Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akro#NASDAQ">AKRO</a>) shares fell 63.9% to $17.52 after the company reported a 36-week analysis of its Phase 2b SYMMETRY study evaluating the efficacy and safety of its lead product candidate efruxifermin.
Athersys, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/athx#NASDAQ">ATHX</a>) dipped 46% to $0.1620 after the company reported interim analysis results of MASTERS-2 clinical study with multistem in ischemic stroke and signed a Memorandum of Understanding for global ARDS license with Healios.
89bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etnb#NASDAQ">ETNB</a>) fell 37.7% to $9.68.
HUB Cyber Security Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hubc#NASDAQ">HUBC</a>) fell 32% to $0.4547.
Gamer Pakistan Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gpak#NASDAQ">GPAK</a>) declined 27% to $1.63. Gamer Pakistan priced its IPO at $4 per share.
ParaZero Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/przo#NASDAQ">PRZO</a>) shares declined 23.7% to $2.06. ParaZero Technologies shares jumped 133% on Monday after the company announced an Australian regulator approved first commercial drone flights in populated areas and near people using ParaZero safety systems..
Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) dipped 22.1% to $23.38 after the company announced results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis.
Molekule Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mkul#NASDAQ">MKUL</a>) shares fell 21.7% to $0.1009 after gaining around 5% on Monday.
Maris-Tech Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtek#NASDAQ">MTEK</a>) fell 21.6% to $1.09.
Maison Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mss#NASDAQ">MSS</a>) fell 20% to $5.20, after dipping 11% on Monday.
Fitell Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ftel#NASDAQ">FTEL</a>) fell 15.3% to $1.60.
Nxu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxu#NASDAQ">NXU</a>) declined 14% to $0.1290
Phoenix Motor Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pev#NASDAQ">PEV</a>) fell 11.3% to $1.40, after surging 58% on Monday. Phoenix Motor said its EdisonFuture subsidiary launched new Proton Exchange Membrane (PEM) solutions for green hydrogen products and production.
Safe and Green Development Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgd#NASDAQ">SGD</a>) declined 11.3% to $1.2501.
John Wiley &amp; Sons, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wly#NYSE">WLY</a>) declined 10.4% to $31.02 after reporting a CEO transition.
Falcon&#39;s Beyond Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fbyd#NASDAQ">FBYD</a>) fell 9.6% to $13.50.
Lipella Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lipo#NASDAQ">LIPO</a>) fell 9.5% to $0.95.
RVL Pharmaceuticals plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvlp#NASDAQ">RVLP</a>) shares fell 9.2% to $0.1732, after jumping over 50% on Monday.
Groupon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grpn#NASDAQ">GRPN</a>) fell 9% to $13.83.
Borqs Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brqs#NASDAQ">BRQS</a>) fell 8.6% to $0.9649 after declining more than 13% on Monday. Borqs Technologies recently announced a 1-for-12 reverse stock split.
VIA optronics AG (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/viao#NYSE">VIAO</a>) fell 8.5% to $1.18.
PagerDuty, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pd#NYSE">PD</a>) declined 3.7% to $21.03 after the company announced a proposed private placement of $350 million of convertible senior notes.
Now Read This: <a href="https://www.benzinga.com/news/23/10/35157619/top-3-tech-and-telecom-stocks-you-may-want-to-dump-in-october"> Top 3 Tech And Telecom Stocks You May Want To Dump In October </a>

Borqs Technologies, Inc. - Ordinary Shares

BRQS

CFRX

CISO

COHR

ERAS

FTEL

GRPN

IMUX

LIPO

MDXH

MKUL

Merrill Lynch & Strategic Return Notes for Select 10 Index

MTEK

OPEN

PGTI

PWFL

SVRE

VIAO

Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 250 points on Tuesday.
The Dow traded up 0.81% to 33,876.62 while the NASDAQ rose 1.23% to 13,650.54. The S&amp;P 500 also rose, gaining, 1.10% to 4,383.17.
Check This Out: <a href="https://www.benzinga.com/news/earnings/23/10/35145201/walgreens-likely-to-report-lower-q4-earnings-heres-a-look-at-recent-price-target-changes-by-the-mos"> Walgreens Likely To Report Lower Q4 Earnings; Here&#39;s A Look At Recent Price Target Changes By The Most Accurate Analysts</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Consumer discretionary shares rose by 1.4% on Tuesday.
In trading on Tuesday, energy shares fell by around 0.1%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
U.S. wholesale inventories fell 0.1% month-over-month in August.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
SMX (Security Matters) Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smx#NASDAQ">SMX</a>) shares shot up 99% to $3.3841 after the company announced it secured a majority stake in True Gold Consortium.
Shares of Intrusion Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intz#NASDAQ">INTZ</a>) got a boost, shooting 46% to $0.5094. Intrusion has been awarded a $5 million agreement with a large telecommunications provider to provide Intrusion Shield support for its data centers.
Startek, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/srt#NYSE">SRT</a>) shares were also up, gaining 29% to $4.2191 as the company agreed to be acquired by funds managed by CSP Management Limited for $4.30 per share in cash.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Akero Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akro#NASDAQ">AKRO</a>) shares dropped 66% to $16.72 after the company reported a 36-week analysis of its Phase 2b SYMMETRY study evaluating the efficacy and safety of its lead product candidate efruxifermin.
Shares of Athersys, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/athx#NASDAQ">ATHX</a>) were down 47% to $0.16 after the company reported interim analysis results of MASTERS-2 clinical study with multistem in ischemic stroke and signed a Memorandum of Understanding for global ARDS license with Healios.
Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) was down, falling 24% to $22.95 after the company announced results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis.
Also Check This Out:<a href="https://www.benzinga.com/news/23/10/35158866/check-out-3-high-yielding-dividend-stocks-in-energy-sector-from-wall-streets-most-accurate-analysts"> Check Out 3 High-Yielding Dividend Stocks In Energy Sector From Wall Street&#39;s Most Accurate Analysts</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 1% to $85.53 while gold traded up 0.3% at $1,869.50.
Silver traded up 0.2% to $21.96 on Tuesday while copper fell 0.9% to $3.6145.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were higher today. The eurozone&rsquo;s STOXX 600 gained 1.8% London&rsquo;s FTSE 100 gained 1.74% while Spain&rsquo;s IBEX 35 Index rose 2.3% The German DAX rose 1.86% French CAC 40 climbed 1.84%, while Italy&rsquo;s FTSE MIB Index gained 2.3%.
Industrial production in Italy rose 0.2% month-over-month in August following a revised 0.9% fall in July. Retail sales in the UK rose 2.8% from a year ago in September.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly higher on Tuesday, with Japan&rsquo;s Nikkei 225 gaining 2.43%, China&rsquo;s Shanghai Composite Index falling 0.70% and Hong Kong&rsquo;s Hang Seng Index gaining 0.84%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, rose 0.9%.
Japan&#39;s current account surplus narrowed to JPY 2.280 trillion in August from JPY 2.772 trillion in the prior month, compared to market estimates of JPY 3.091 trillion.
&nbsp;
<h3>Economics</h3>
&nbsp;
The NFIB Small Business Optimism Index fell for a second month to a reading of 90.8 in September from 91.3 in the prior month.
U.S. wholesale inventories fell 0.1% month-over-month in August.
Now Read This: <a href="https://www.benzinga.com/news/23/10/35157619/top-3-tech-and-telecom-stocks-you-may-want-to-dump-in-october"> Top 3 Tech And Telecom Stocks You May Want To Dump In October</a>

S&P 500 Rises 1%; US Wholesale Inventories Fall In August

WIIM

Athersys shares are trading lower after the company said it intends to conduct additional data analysis with independent statisticians because the sample size in the Phase 3 MASTERS-2 is insufficiently powered to achieve the primary endpoint.

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 50 points on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.19% to 33,668.96 while the NASDAQ rose 0.16% to 13,505.57. The S&amp;P 500 also rose, gaining, 0.18% to 4,343.67.
Check This Out: <a href="https://www.benzinga.com/news/earnings/23/10/35145201/walgreens-likely-to-report-lower-q4-earnings-heres-a-look-at-recent-price-target-changes-by-the-mos"> Walgreens Likely To Report Lower Q4 Earnings; Here&#39;s A Look At Recent Price Target Changes By The Most Accurate Analysts</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Consumer staples shares rose by 0.8% on Tuesday.
In trading on Tuesday, real estate shares fell by around 0.3%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
PepsiCo Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pep#NASDAQ">PEP</a>) reported better-than-expected earnings for its third quarter on Tuesday.
The company posted third-quarter FY23 sales growth of 6.7% year-on-year to $23.45 billion, beating the analyst consensus estimate of $23.43 billion. Adjusted EPS of $2.25 beat the consensus estimate of $2.15.
PepsiCo continues to expect FY23 organic revenue growth of 10%. For FY23, the company now expects to deliver 13% core constant currency EPS growth (previously 12%). The company raised its FY23 adjusted EPS outlook from $7.47 to $7.54 versus the consensus of $7.49.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
SMX (Security Matters) Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smx#NASDAQ">SMX</a>) shares shot up 92% to $3.2581 after the company announced it secured a majority stake in True Gold Consortium.
Shares of SuperCom Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spcb#NASDAQ">SPCB</a>) got a boost, shooting 82% to $0.6560, after falling 13% on Monday.
CISO Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciso#NASDAQ">CISO</a>) shares were also up, gaining 56% to $0.2168. CISO Global said its Argo Edge Cloud Security Platform has been independently valued at $49 million.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Akero Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akro#NASDAQ">AKRO</a>) shares dropped 61% to $18.87 after the company reported a 36-week analysis of its Phase 2b SYMMETRY study evaluating the efficacy and safety of its lead product candidate efruxifermin.
Shares of Athersys, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/athx#NASDAQ">ATHX</a>) were down 61% to $0.1180 after the company reported interim analysis results of MASTERS-2 clinical study with multistem in ischemic stroke and signed a Memorandum of Understanding for global ARDS license with Healios.
89bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etnb#NASDAQ">ETNB</a>) was down, falling 31% to $10.64.
Also Check This Out:<a href="https://www.benzinga.com/news/23/10/35158866/check-out-3-high-yielding-dividend-stocks-in-energy-sector-from-wall-streets-most-accurate-analysts"> Check Out 3 High-Yielding Dividend Stocks In Energy Sector From Wall Street&#39;s Most Accurate Analysts</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 0.4% to $86.07 while gold traded up 0.2% at $1,868.00.
Silver traded down 0.6% to $21.79 on Tuesday while copper fell 1.3% to $3.5985.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were higher today. The eurozone&rsquo;s STOXX 600 gained 1.5% London&rsquo;s FTSE 100 gained 1.6% while Spain&rsquo;s IBEX 35 Index rose 1.8% The German DAX rose 1.5% French CAC 40 climbed 1.4%, while Italy&rsquo;s FTSE MIB Index gained 1.8%.
Industrial production in Italy rose 0.2% month-over-month in August following a revised 0.9% fall in July. Retail sales in the UK rose 2.8% from a year ago in September.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly higher on Tuesday, with Japan&rsquo;s Nikkei 225 gaining 2.43%, China&rsquo;s Shanghai Composite Index falling 0.70% and Hong Kong&rsquo;s Hang Seng Index gaining 0.84%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, rose 0.9%.
Japan&#39;s current account surplus narrowed to JPY 2.280 trillion in August from JPY 2.772 trillion in the prior month, compared to market estimates of JPY 3.091 trillion.
&nbsp;
<h3>Economics</h3>
&nbsp;
The NFIB Small Business Optimism Index fell for a second month to a reading of 90.8 in September from 91.3 in the prior month.
Now Read This: <a href="https://www.benzinga.com/news/23/10/35157619/top-3-tech-and-telecom-stocks-you-may-want-to-dump-in-october"> Top 3 Tech And Telecom Stocks You May Want To Dump In October</a>

US Stocks Gain; PepsiCo Posts Upbeat Earnings

<h3>Gainers</h3>
<ul>
<li>Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) shares rose 18.9% to $1.89 during Tuesday's pre-market session. The market value of their outstanding shares is at $84.2 million. </li>
<li>MDxHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXH#NASDAQ">MDXH</a>) stock rose 16.1% to $2.74. The company's market cap stands at $74.0 million. </li>
<li>Synlogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYBX#NASDAQ">SYBX</a>) shares increased by 14.5% to $3.0. The market value of their outstanding shares is at $25.4 million. </li>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) stock increased by 14.2% to $0.41. The market value of their outstanding shares is at $109.9 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) stock moved upwards by 13.27% to $0.52. The market value of their outstanding shares is at $15.4 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares increased by 12.58% to $1.61. The company's market cap stands at $7.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>) stock fell 58.2% to $20.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.1 billion. </li>
<li>Athersys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHX#NASDAQ">ATHX</a>) stock fell 32.94% to $0.2. The market value of their outstanding shares is at $5.3 million. </li>
<li>89bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETNB#NASDAQ">ETNB</a>) stock declined by 27.56% to $11.25. The market value of their outstanding shares is at $849.1 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares fell 23.21% to $0.46. The market value of their outstanding shares is at $4.1 million. </li>
<li>Ventyx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) stock decreased by 16.3% to $25.11. The company's market cap stands at $1.4 billion. </li>
<li>RVL Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVLP#NASDAQ">RVLP</a>) shares decreased by 16.15% to $0.16. The market value of their outstanding shares is at $17.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ISPC

NAOV

SYBX

Athersys, Inc. Shares To Resume Trade At 9:00 a.m. ET

The MOU includes $1.5M to $4.5M near term payments plus up to $150M in milestones
Athersys, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ATHX#NASDAQ">ATHX</a>), a cell therapy and regenerative medicine company developing MultiStem&#xAE; (invimestrocel) for critical care indications, announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company's ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem&#xAE; for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients is insufficiently powered to achieve the primary endpoint of mRS Shift analysis at Day 365. There were no safety issues identified. Because the sample size required to achieve statistical significance is considerably larger, Athersys intends to conduct additional data analysis with independent statisticians. The Company plans to pause enrollment of new patients while this analysis is being conducted.
Separately, Athersys announces that it has entered into a Memorandum of Understanding (MOU) granting HEALIOS K.K. (Healios) global rights to develop and commercialize MultiStem for the treatment of acute respiratory distress syndrome (ARDS). Under the terms of the MOU, Athersys will receive between $1.5M and $4.5M in near term payments with up to $150 million in potential development and sales milestones and additional royalties. Athersys also expects to receive revenue from the sale of existing clinical doses of MultiStem-- which were manufactured in accordance with its 3D bioreactor process that earlier this year received approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA)--for Healios to use in its Phase 3 clinical trial in ARDS.
Athersys intends to continue exploring available strategic options. However, in the event Athersys is unable in the near-term to enter into a strategic transaction or obtain adequate financing, it expects to have to file for protection under the bankruptcy laws to allow the Company to conduct an orderly wind down of operations. In the interim, the Company is streamlining its operations to preserve its capital and cash resources.
"I'd like to thank the many patients, clinicians and vendors that have supported this pivotal phase 3 trial since its start in 2018. We're disappointed with the results of the unblinded interim analysis indicating a large sample size adjustment would be required to achieve our primary endpoint. We intend to conduct further analysis to better understand these results. The new MOU we've signed with Healios for ARDS provides the company near-term capital and the potential for meaningful milestone payments as we continue to pursue various strategic solutions," said Dan Camardo, Chief Executive Officer of Athersys.
About MultiStem&#xAE;
MultiStem&#xAE; (invimestrocel) cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. MultiStem therapy's potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The therapy represents a unique "off-the-shelf" stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent tolerability demonstrated in clinical studies, we believe that MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need.

Biotech

Contracts

General

Athersys Reports Interim Analysis Results Of MASTERS-2 Clinical Study With MultiStem In Ischemic Stroke, Signs Memorandum Of Understanding For Global ARDS License With Healios; Includes $1.5M To $4.5M Near Term Payments Plus Up To $150M In Milestones

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Athersys&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/athx-stock-quote/">ATHX</a>) stock is falling on Friday after the biotechnology company announced a <a href="https://www.businesswire.com/news/home/20230817444406/en/Athersys-Inc.-Announces-Pricing-of-3.5-Million-Public-Offering">public stock offering</a>.
That public offering has Athersys selling 10,937,500 shares of ATHX stock for a price of 32 cents each. To go along with this, the company is issuing 10,937,500 units of Series A warrants and 10,937,500 units of Series B warrants. The warrants each have an exercise price of 32 cents.
According to Athersys, it expects this public stock offering to raise $3.5 million in gross proceeds. The company says that it intends to use this money for general corporate purposes. This offering closes on Monday.
<h2>How This Affects ATHX Stock</h2>
With this public stock offering, Athersys is increasing its total number of outstanding shares. A side effect of that is it dilutes the stakes of current investors in the company. That&rsquo;s one reason it has ATXH stock down today.
In addition to that, the shares priced at 32 cents are below their prior closing price of 39 cents. That means the public offering price is a discount to the current trading price. This is another reason the offering is weighing on ATXH stock.
Today&rsquo;s news also brings with it heavy trading of ATHX shares. As of this writing, more than 365,000 shares of the stock have changed hands. That&rsquo;s already above its daily average trading volume of about 237,000 shares.
ATHX stock is down 35.7% as of Friday morning.
Investors can catch up on all of the latest stock market news worth reading about below!
We&rsquo;re offering up all of the most recent stock market news traders need to know about on Friday! That includes why shares of Farfetch&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/ftch-stock-quote/">FTCH</a>) stock, Avalo Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/avtx-stock-quote/">AVTX</a>) stock, and Neptune Wellness Solutions&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nept-stock-quote/">NEPT</a>) stock are moving today. All of that news is ready at the following links!
<h2>More Stock Market News For Friday</h2>
<ul>
<li><a href="https://investorplace.com/2023/08/why-is-farfetch-ftch-stock-down-43-today/">Why Is Farfetch (FTCH) Stock Down 43% Today?</a></li>
<li><a href="https://investorplace.com/2023/08/why-is-avalo-therapeutics-avtx-stock-up-19-today/">Why Is Avalo Therapeutics (AVTX) Stock Up 19% Today?</a></li>
<li><a href="https://investorplace.com/2023/08/why-is-neptune-wellness-solutions-nept-stock-up-72-today/">Why Is Neptune Wellness Solutions (NEPT) Stock Up 72% Today?</a></li>
</ul>
On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;<a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;&nbsp;<a href="http://investorplace.com/">InvestorPlace.com</a>&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.&nbsp;
Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">How to Profit Without Getting Scammed</a>
<h3>More From InvestorPlace</h3>
<ul>
<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT758389">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT758391">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT758395">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
<li>
						<a href="https://investorplace.com/2022/06/this-could-be-the-best-deal-in-the-history-of-independent-investing-research/?cid=MKT638063&amp;eid=MKT758393">The $1 Investment You MUST Take Advantage of Right Now</a>
					</li>
</ul>
<div>
<div>
<div></div>
<div></div>
</div>
</div>
The post <a href="https://investorplace.com/2023/08/why-is-athersys-athx-stock-down-36-today/">Why Is Athersys (ATHX) Stock Down 36% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Athersys (ATHX) Stock Down 36% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Applied Materials (NASDAQ:<a href="https://investorplace.com/stock-quotes/amat-stock-quote/">AMAT</a>) stock is climbing higher on Friday after getting new price targets following its latest earnings report.
Morgan Stanley analyst Joseph Moore starts us off by increasing his price target for AMT stock from <a href="https://seekingalpha.com/news/4004301-applied-materials-rises-as-wall-street-praises-strength-in-trailing-edge-nodes">$125 per share to $139 per share</a>. He did so while maintaining the firm&rsquo;s &ldquo;equal-weight&rdquo; rating for the company&rsquo;s shares.
Next is J.P. Morgan analyst Harlan Sur raising his price target for AMT stock from $145 per share to $165 per share. This comes alongside an &ldquo;overweight&rdquo; rating for the semiconductor company&rsquo;s shares.
Bank of America also joined the price target increase spree for AMAT stock. This saw the firm&rsquo;s analysts setting a <a href="https://www.marketbeat.com/stocks/NASDAQ/AMAT/price-target/">new price target of $175 per share</a>, as compared to the prior price target of $165 per share.
Finally, Berenberg Bank is the last firm we&rsquo;re covering today increasing their price target for AMAT shares. Its analysts raised their price target for the company&rsquo;s shares from $150 each to $175 each.
<h2>What To Expect From AMAT Stock</h2>
With all of these new price targets in place, investors might wonder about the overall stance on AMAT stock. The current analysts&rsquo; consensus price prediction for the company&rsquo;s shares is $147.12. That comes with a consensus rating of &ldquo;moderate buy&rdquo; based on 28 opinions.
AMAT stock is up roughly 1% as of Friday morning. That comes as some 2.6 million shares change hands. For comparison, its daily average trading volume is about 5.9 million shares.
Investors wanting even more of the latest stock market stories will want to keep reading!
We have breakdowns of all the biggest stock market news worth reading about on Friday! A few examples include what has Chinese stocks down today, a cut price target for AMC Entertainment&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/amc-stock-quote/">AMC</a>) stock, as well as details on Athersys&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/athx-stock-quote/">ATHX</a>) stock falling today. All of that info is available by checking the links below!
<h2>More Friday Stock Market News</h2>
<ul>
<li><a href="https://investorplace.com/2023/08/why-are-chinese-stocks-baba-jd-pdd-nio-down-today/">Why Are Chinese Stocks BABA, JD, PDD, NIO Down Today?</a></li>
<li><a href="https://investorplace.com/2023/08/amc-stock-alert-citi-slashes-price-target-to-1-55/">AMC Stock Alert: Citi Slashes Price Target to $1.55</a></li>
<li><a href="https://investorplace.com/2023/08/why-is-athersys-athx-stock-down-36-today/">Why Is Athersys (ATHX) Stock Down 36% Today?</a></li>
</ul>
On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
<ul>
<li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT758392">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT758390">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT758396">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
<li>
						<a href="https://investorplace.com/2022/06/this-could-be-the-best-deal-in-the-history-of-independent-investing-research/?cid=MKT638063&amp;eid=MKT758394">The $1 Investment You MUST Take Advantage of Right Now</a>
					</li>
</ul>
<div>
<div>
<div></div>
<div></div>
</div>
</div>
The post <a href="https://investorplace.com/2023/08/amat-stock-alert-analysts-raise-applied-materials-price-targets-after-earnings/">AMAT Stock Alert: Analysts Raise Applied Materials Price Targets After Earnings</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AMAT Stock Alert: Analysts Raise Applied Materials Price Targets After Earnings

Athersys files to sell 15.36M shares for holders